Skip to main content

Table 3 Six overlapping SNPs in PPARGC1B associated with ER-positive breast cancer in Swedish and Finnish samples

From: Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer

SNP

Allelea

Subtype

Swedish sample

Finnish sample

   

MAFb

ORc (95% CI)

MAFb

ORc (95% CI)

rs4705365

G/A

ER+

0.21

1.26 (1.05, 1.52)

0.17

1.26 (1.05, 1.52)

  

ER-

 

1.14 (0.81, 1.61)

 

1.17 (0.9, 1.52)

  

All cases

 

1.14 (0.97, 1.33)

 

1.18 (0.99, 1.4)

rs6895698

G/A

ER+

0.22

1.27 (1.06, 1.53)

0.17

1.39 (1.15, 1.67)

  

ER-

 

1.05 (0.74, 1.48)

 

1.14 (0.88, 1.49)

  

All cases

 

1.12 (0.96, 1.3)

 

1.25 (1.05, 1.49)

rs2340621

G/A

ER+

0.31

1.3 (1.08, 1.57)

0.32

1.22 (1.03, 1.46)

  

ER-

 

0.86 (0.61, 1.2)

 

1.05 (0.82, 1.34)

  

All cases

 

1.12 (0.96, 1.31)

 

1.14 (0.97, 1.34)

rs10036538

C/G

ER+

0.26

1.19 (0.99, 1.42)

0.22

1.2 (1, 1.43)

  

ER-

 

0.91 (0.65, 1.28)

 

1.05 (0.81, 1.35)

  

All cases

 

1.03 (0.89, 1.2)

 

1.11 (0.94, 1.31)

rs1012543

A/G

ER+

0.26

1.26 (1.05, 1.51)

0.23

1.26 (1.06, 1.5)

  

ER-

 

1.08 (0.77, 1.51)

 

1.08 (0.84, 1.38)

  

All cases

 

1.11 (0.95, 1.29)

 

1.18 (1, 1.39)

rs741581

G/A

ER+

0.08

1.32 (1.05, 1.67)

0.05

1.76 (1.33, 2.31)

  

ER-

 

0.81 (0.49, 1.32)

 

1.21 (0.81, 1.82)

  

All cases

 

1.12 (0.92, 1.37)

 

1.53 (1.18, 1.98)

  1. ER+, estrogen receptor-positive; ER-, estrogen receptor-negative; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval. aMajor allele/minor allele. bFrom control samples only. cORs were performed on a dominant model, age-unadjusted analysis in the Swedish sample and age-adjusted analysis in the Finnish sample.